Rabkin Charles S, Hirt Carsten, Janz Siegfried, Dölken Gottfried
Viral Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20892, USA.
J Natl Cancer Inst Monogr. 2008(39):48-51. doi: 10.1093/jncimonographs/lgn002.
The chromosomal translocation t(14;18)(q32;q21) is characteristic of follicular lymphoma and a frequent abnormality in other types of non-Hodgkin lymphoma (NHL). In healthy individuals, the same translocation may also be found in a small fraction of peripheral blood lymphocytes, the biological significance of which is beginning to be explored. Translocation prevalence and frequency are potential risk factors for developing NHL. Here, we review the published data and describe recent and ongoing work on this promising biomarker. We have a series of studies in four major areas: 1) t(14;18) prevalence and frequency in healthy individuals; 2) maturation of translocation-harboring cells; 3) effect of rituximab treatment on t(14;18) carriage; and 4) predictive and clonotypic relationship between t(14;18) and follicular lymphoma or other NHL. Further studies are warranted to increase understanding of this crucial molecular event in the development of hematopoietic malignancies. Potential applications include determination of elevated risk for lymphoma, early detection of disease, and identification of molecular targets for preventive interventions.
染色体易位t(14;18)(q32;q21)是滤泡性淋巴瘤的特征,也是其他类型非霍奇金淋巴瘤(NHL)常见的异常情况。在健康个体中,同样的易位也可能在一小部分外周血淋巴细胞中发现,其生物学意义正开始被探索。易位的患病率和频率是发生NHL的潜在危险因素。在此,我们回顾已发表的数据,并描述关于这一有前景的生物标志物的近期和正在进行的研究工作。我们有一系列在四个主要领域的研究:1)健康个体中t(14;18)的患病率和频率;2)携带易位细胞的成熟;3)利妥昔单抗治疗对t(14;18)携带情况的影响;4)t(14;18)与滤泡性淋巴瘤或其他NHL之间的预测和克隆型关系。有必要进行进一步研究以增进对造血系统恶性肿瘤发生过程中这一关键分子事件的理解。潜在应用包括确定淋巴瘤风险升高、疾病的早期检测以及识别预防性干预的分子靶点。